The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
29 November 2018
Melanoma Institute Australia (MIA) is proud to play a vital role in the Australian Cancer Research Foundation (ACRF) Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID).
Fifteen 3D total-body imaging systems will be rolled out across Queensland, New South Wales and Victoria with the aim of improving detection of early-stage melanoma and saving lives. MIA’s The Poche Centre will host one of the 3D systems.
It is estimated each 3D imaging machine will be able to provide 3,000 examinations each year, resulting in a total of approximately 100,000 digital ‘avatars’ within three years. This will create a world-wide data set of skin images which will inform clinical studies that will ultimately lead to changes in clinical decision making.
Funded by a highly competitive and prestigious $10 million grant from the ACRF, ACEMID is led by the University of Queensland, along with The University of Sydney and Monash University. It brings together three established NHMRC Centres of Research Excellence (CRE), including the CRE in Melanoma in which MIA leads, to combine cutting-edge imaging technology with a remote medicine network. Melanoma Institute Australia’s team members critical to the initiative include Professor Graham Mann, who is the NSW Chief Investigator (CI), and MIA Co-Medical Director Professor Richard Scolyer and Associate Professor Pascale Guitera who are experts in Diagnostic Intelligence. MIA’s Professor Andrew Spillane and Associate Professor Robyn Saw are Associate Investigators and Associate Professor Anne Cust and Associate Professor Rachael Morton feature in Clinical and Health Service Evaluation roles.
Co-Medical Director of MIA, Professor Richard Scolyer, said the initiative would provide enhanced access to specialist services for patients in rural and remote areas.
‘This infrastructure will provide the foundation for 3D total body imaging to be implemented within a remote medicine network, which is essential in a country as vast as Australia,’ Professor Scolyer said.
‘Three dimensional total body data will be transmitted from 3D imaging systems in geographically diverse locations to centralised image storage repositories, which will enable dermatologists and other skin specialists to review patient images. This will have immense impacts on patients by ensuring they are diagnosed quickly, early and accurately, regardless of where they live.’
The ACRF Australian Centre of Excellence in Melanoma Imaging and Diagnosis is a world first approach to tackling the burden of melanoma, and aims to achieve a “World Without Melanoma”. It will create a multi-disciplinary, multi-site team with the goal of improving the detection and diagnosis of melanoma whilst reducing variability in diagnosis and the incidence of thicker, poorer prognosis melanomas. The initiative also aims to reduce the financial burden of melanoma on the Australian public, decrease consultation times by taking a total-body image in milliseconds, and improve the health equity of rural and remote Australians in regards to melanoma diagnosis.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.
Professor’s Long and Scolyer are well known in the academic community and beloved by their patients. But we wanted to get to know our new Conjoint Medical Directors a little more and hear their plans on making an impact on melanoma.